Expert consensus on the management of adverse events of ErbB family tyrosine kinase inhibitors in breast cancer
10.3760/cma.j.cn112152-20200805-00711
- VernacularTitle:乳腺癌靶向人表皮生长因子受体2酪氨酸激酶抑制剂不良反应管理共识
- Author:
Biyun WANG
1
;
Rui GE
;
Zefei JIANG
Author Information
1. 复旦大学附属肿瘤医院肿瘤内科，上海 200032
- Keywords:
Breast neoplasms;
Human epidermal growth factor receptor 2;
Tyrosine kinase inhibitors;
Adverse event;
Expert consensus
- From:
Chinese Journal of Oncology
2020;42(10):798-806
- CountryChina
- Language:Chinese
-
Abstract:
Human epidermal growth factor receptor-2 (HER-2) tyrosine kinase inhibitors (TKI) is the targeted drug of HER-2-positive breast cancer. Lapatinib, pyrotinib and neratinib, as ErbB family TKIs, have been approved by National Medical Products Administration and applied in the treatment of HER-2 positive breast cancer in China. The most common adverse effects (AEs) of TKI agents include diarrhea, drug-induced liver injury (DILI), nausea, vomiting, skin toxicity, cardiotoxicity and oral mucositis. The Breast Cancer Expert Group of Chinese Society of Clinical Oncology (CSCO) summarized the incidence and characteristics of AEs of TKI, evaluated the manifestations and severity of AEs, and formulated the consensus of the management of common AEs based on the clinical experiences and updated advances from domestic and abroad studies. This consensus aims to provide the practical strategy for clinicians in the management of ErbB-family TKI-related AEs in China, and eventually enhance the patients′ compliance and improve the therapeutic efficacy.
